Amgen 145 Study Shows No Difference In Risk Of Death In Aranesp-Treated Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Outcome could help to stabilize the use of erythropoiesis-stimulating agents in anemia patients in the oncology setting.